E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Impaired VE/CO2 on cardio pulmonary exercise testing |
|
E.1.1.1 | Medical condition in easily understood language |
impaired cardiac function |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cardiovascular Diseases [C14] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10007648 |
E.1.2 | Term | Cardiovascular disease, unspecified |
E.1.2 | System Organ Class | 100000004849 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The study objective is to assess the effect of bisoprolol on heart function in high-risk surgical patients through assessment of exercise testing and a reduction in VE/VCO2 |
|
E.2.2 | Secondary objectives of the trial |
The secondary objectives are to assess the effect of bisoprolol on heart function in high-risk surgical patients through assessment of anaerobic threshold and evidence of heart abnormality. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- Aged 55 years or over - Scheduled for major intra-abdominal surgery - Presenting for routine CPET as part of pre-assessment - Not currently taking any BB medication and not taken BB medication within 1 month prior - Consent to GP being informed - VE/VCO2 greater than 34 on CPET, as either the value measured at VO2@AT, or the lowest measured value, plus at least one of the following: - Presence of a known history of a clinical risk factor for major adverse cardiac events (MACE) after surgery Ischaemic heart disease Cerebrovascular disease Renal insufficiency (creatinine > 170 mol.L-1) Chronic heart failure
- Evidence of abnormal myocardial response on exercise testing - Flattened or inflecting oxygen uptake to heart rate response (oxygen pulse response, VO2/HR, panel 2) - Flattened or inflecting oxygen uptake to work rate response (VO2/Watt, panel 3) - Anaerobic threshold <11mls/kg/min
|
|
E.4 | Principal exclusion criteria |
- Refusal or unable to give informed consent - Fewer than 7 days before scheduled surgery at pre-assessment appointment surgery - Current Beta blocker medication or having taken any Beta blocker within 1 month prior - Contra-indications to BB medication including: o bronchial asthma o reversible airways disease o decompensated heart failure (NYHA class IV) o fluid overloaded o hypotensive o severe liver impairment o second or third degree A-V block (unless pacemaker fitted) o SA block o sick sinus syndrome (unless pacemaker inserted) o cardiogenic shock o bradycardia (heart rate less than 60 bpm) o Prinzmetal's angina o Untreated Phaeochromocytoma o metabolic acidosis o poor blood circulation in the hands and feet o severe peripheral arterial insufficiency o known hypersensitivity to bisoprolol or its ingredients (lactose monohydrate, silica colloidal anhydrous, crospovidone (Type A), crospovidone (Type B), povidone 30, sucrose, magnesium stearate) o co-prescription with negative chronotropic agents such as digoxin, diltiazem, verapamil, amiodarone o co-prescription with medications that affect the plasma concentrations of bisoprolol such as rifampin, cimetidine, quinidine, fluoxetine, paroxetine, propafenone, digoxin, reserpine, monoamine oxidase inhibitors, clonidine
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The effect on the ventilator equivalent for CO2 (VE/VCO2) as measured at anaerobic threshold or nadir, after introduction of beta-blockade |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Evaluation of the primary end point can be made after the last patient has had their second measurement of their ventilator equivalent for CO2 (VE/VCO2) |
|
E.5.2 | Secondary end point(s) |
1. Anaerobic threshold pre- and post-bisoprolol 2. Evidence of myocardial abnormality on CPET (VO2/HR response, VO2/Watt response) pre- and post-bisoprolol
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Evaluation of the secondary end points can be made after the last patient has had their second measurement of the above measures. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | No |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The end of the trial will be when the last patient has had their second CPET performed. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 4 |
E.8.9.1 | In the Member State concerned days | 31 |
E.8.9.2 | In all countries concerned by the trial years | 3 |
E.8.9.2 | In all countries concerned by the trial months | 4 |
E.8.9.2 | In all countries concerned by the trial days | 31 |